TCGA-50-5072-01A-21R-1858-07
— · cohortA4
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA4
- subtype
- cohortA4
- age_years
- 74
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.480
- G2M_CHECKPOINT+0.450
- MYC_TARGETS_V1+0.440
- MYC_TARGETS_V2+0.420
- PANCREAS_BETA_CELLS+0.390
- ESTROGEN_RESPONSE_LATE+0.360
- MTORC1_SIGNALING+0.360
- SPERMATOGENESIS+0.350
- ANGIOGENESIS+0.320
- COAGULATION+0.310
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.290
- HEDGEHOG_SIGNALING-0.280
- WNT_BETA_CATENIN_SIGNALING-0.190
- IL6_JAK_STAT3_SIGNALING-0.090
- P53_PATHWAY-0.090
- HEME_METABOLISM-0.070
- INFLAMMATORY_RESPONSE-0.070
- KRAS_SIGNALING_DN-0.040
- IL2_STAT5_SIGNALING-0.030
- INTERFERON_GAMMA_RESPONSE-0.030
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR15030865 | — | — | 0.832 |
| 2 | MNG544 | — | — | 0.824 |
| 3 | AUR-AFR3-TTP1-A-2-1-R-A743-41 | — | C | 0.804 |
| 4 | SRR10900569 | — | — | 0.799 |
| 5 | SRR1313157 | — | E | 0.789 |
| 6 | TCGA-78-7150-01A-21R-2039-07 | — | cohortA4 | 0.785 |
| 7 | f34c57ee-92a6-4e3b-acde-7fd631c42f87 | — | — | 0.780 |
| 8 | TCGA-73-4670-01A-01R-1206-07 | — | cohortA4 | 0.778 |
| 9 | MNG778 | — | — | 0.777 |
| 10 | TCGA-E9-A1RB-01A-11R-A157-07 | — | C | 0.774 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 36 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.480 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.450 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.440 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.420 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.390 | Cobimetinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.360 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.360 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.350 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.320 | Remibrutinib | — uncovered |
| COAGULATION | 0.310 | Binimetinib | — uncovered |
| ADIPOGENESIS | 0.280 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.280 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.270 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.270 | Remibrutinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.270 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.250 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.230 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.220 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.220 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.200 | Idelalisib | — uncovered |